CryoPort (NASDAQ:CYRX) Issues Earnings Results, Misses Estimates By $0.02 EPS

CryoPort (NASDAQ:CYRX) announced its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), Zacks reports. The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%.

Here are the key takeaways from CryoPort’s conference call:

• Full-year revenue from continuing operations was $176.2M, above the prior guidance range, with Q4 double-digit growth; management guided 2026 revenue of $190M–$194M and expects positive adjusted EBITDA in H2 2026.
• Commercial cell & gene therapy momentum accelerated—commercial revenue rose 29% and now represents ~20% of revenue, while Cryoport supports a record 760 clinical trials and 20 commercial therapies, with 86 phase‑3 and 361 phase‑2 trials described as a “spring‑loaded” pipeline for future commercial revenue.
• Operational discipline and product innovation showed progress: gross margin improved to 47% with a $12M YoY adjusted EBITDA improvement, plus investments in global supply‑chain centers and new MVE product offerings (Fusion 800, CryoVerse, integrated monitoring) and enterprise AI adoption.
• The sale of CRYOPDP to DHL delivered a meaningful capital infusion and a strategic partnership expected to expand APAC/EMEA reach, but management noted integration and full benefit realization will take time.
• Guidance and upside remain sensitive to regulatory approvals, macro volatility and timing of commercial therapy ramps; product (MVE) sales are lumpy and management modeled only mid‑single‑digit product growth, leaving downside risk if approvals or commercial rollouts slow.

CryoPort Stock Performance

Shares of CryoPort stock traded up $0.71 during mid-day trading on Wednesday, hitting $9.20. 253,062 shares of the stock were exchanged, compared to its average volume of 351,563. The company has a 50-day simple moving average of $9.51 and a 200 day simple moving average of $9.41. The company has a market capitalization of $460.64 million, a P/E ratio of 7.86 and a beta of 1.69. CryoPort has a 12 month low of $4.63 and a 12 month high of $11.45. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77.

Insider Buying and Selling

In other news, Director Ramkumar Mandalam sold 11,570 shares of the company’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the transaction, the director owned 80,758 shares of the company’s stock, valued at $806,772.42. This represents a 12.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the period. Quadrature Capital Ltd bought a new position in shares of CryoPort during the 4th quarter valued at approximately $97,000. Corient Private Wealth LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at $113,000. BNP Paribas Financial Markets lifted its stake in CryoPort by 55.2% in the third quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after purchasing an additional 4,225 shares during the last quarter. Finally, Creative Planning purchased a new position in CryoPort during the 2nd quarter valued at $96,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort News Summary

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target on CYRX from $12 to $13 and reiterated a “buy” rating, implying meaningful upside versus current levels. Article Title
• Positive Sentiment: Revenue beat and FY 2025 growth — CryoPort reported Q4 revenue of $45.45M (above consensus ~$42.9M) and FY 2025 revenue of $176.2M, with Life Sciences Services up 18% and commercial cell & gene therapy revenue up 29% YoY. These top-line trends support the company’s growth narrative. Press Release
• Neutral Sentiment: FY 2026 revenue guidance in line to slightly above consensus — CryoPort guided FY 2026 revenue to $190.0M–$194.0M (≈8%–10% growth y/y), roughly matching the consensus (~$189.4M). Guidance reduces downside risk but isn’t a major beat. Guidance Details
• Neutral Sentiment: Earnings call and analyst coverage — The Q4 2025 earnings call transcript and several earnings outlook pieces were published (useful for details and management commentary). Earnings Transcript
• Neutral Sentiment: Short-interest data appears unreliable — Recent short-interest entries report zeros/NaN and a 0.0 days ratio, indicating either negligible reported shorting or a reporting anomaly; this is unlikely to be a driver until clarified. (No direct link available.)
• Negative Sentiment: EPS miss — CryoPort reported Q4 EPS that missed consensus (company-reported ($0.27) vs. consensus ~($0.19)), showing a larger-than-expected quarterly loss which weighs on near-term profitability expectations. Zacks Article

Wall Street Analyst Weigh In

CYRX has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. UBS Group increased their price objective on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Needham & Company LLC upped their price objective on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.